CARGo - Anti - HLA-G CAR-T Cell Therapy(MD Anderson Cancer Center)

N/A

Report date: 2023/01/06 20:00:55

Base Information

Drug NameCARGo - Anti - HLA-G CAR-T Cell Therapy(MD Anderson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionHLA class I histocompatibility antigen, alpha chain G inhibitors

TargetsHLA class I histocompatibility antigen, alpha chain G

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A